{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:20:07Z","timestamp":1790713207300,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.bmc.2022.116647","type":"journal-article","created":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T19:59:33Z","timestamp":1643486373000},"page":"116647","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Design, synthesis and biological evaluation of novel 1, 3, 4-oxadiazole derivatives as potent neuraminidase inhibitors"],"prefix":"10.1016","volume":"57","author":[{"given":"Wei","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Ping Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Ling Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2022.116647_b0005","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1021\/acs.molpharmaceut.0c00244","article-title":"Synthesis of a hexavalent betulinic acid derivative as a hemagglutinin-targeted influenza virus entry inhibitor","volume":"17","author":"Chen","year":"2020","journal-title":"Mol Pharm"},{"key":"10.1016\/j.bmc.2022.116647_b0010","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1016\/S0264-410X(02)00254-2","article-title":"Realities and enigmas of human viral influenza: pathogenesis, epidemiology and control","volume":"20","author":"Hilleman","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.bmc.2022.116647_b0015","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S0140-6736(99)11433-8","article-title":"Influenza virus neuraminidase inhibitors","volume":"355","author":"Gubareva","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.bmc.2022.116647_b0020","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1080\/14760584.2017.1240041","article-title":"M2- based influenza vaccines: recent advances and clinical potential","volume":"16","author":"Kolpe","year":"2017","journal-title":"Expert Rev Vacc"},{"key":"10.1016\/j.bmc.2022.116647_b0025","doi-asserted-by":"crossref","unstructured":"Young D, Fowler C, Bush K. RWJ-270201 (BCX-1812): a novel neuraminidase inhibitor for influenza. Philos Trans R Soc B. 2001; 356: 1905\u20131913.","DOI":"10.1098\/rstb.2001.1004"},{"key":"10.1016\/j.bmc.2022.116647_b0030","doi-asserted-by":"crossref","first-page":"3482","DOI":"10.1021\/jm0002679","article-title":"BCX-1812 (RWJ-270201): Discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design","volume":"43","author":"Babu","year":"2000","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2022.116647_b0035","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1021\/mp100041b","article-title":"In silico identification of the potential drug resistance sites over 2009 influenza A (H1N1) virus neuraminidase","volume":"7","author":"Liu","year":"2010","journal-title":"Mol Pharm"},{"key":"10.1016\/j.bmc.2022.116647_b0040","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1021\/jm401977j","article-title":"Oseltamivir analogues bearing N-substituted guanidines as potent neuraminidase inhibitors","volume":"57","author":"Mooney","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2022.116647_b0045","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/pro.5560031007","article-title":"Influenza virus neuraminidase: Structure, antibodies, and inhibitors","volume":"3","author":"Colman","year":"1994","journal-title":"Protein Sci"},{"key":"10.1016\/j.bmc.2022.116647_b0050","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nature05114","article-title":"The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design","volume":"443","author":"Russell","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2022.116647_b0055","doi-asserted-by":"crossref","first-page":"8445","DOI":"10.1021\/jm500892k","article-title":"Discovery of N-substituted oseltamivir derivatives as potent and selective inhibitors of H5N1 influenza neuraminidase","volume":"57","author":"Xie","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2022.116647_b0060","doi-asserted-by":"crossref","first-page":"6379","DOI":"10.1021\/acs.jmedchem.8b00929","article-title":"Optimization of N-substituted oseltamivir deriva-tives as potent inhibitors of group-1 and -2 influenza a neuram-inidases, including a drug-resistant variant","volume":"61","author":"Zhang","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2022.116647_b0065","doi-asserted-by":"crossref","unstructured":"Wen WH, Wang SY, Tsai KC, E Cheng YS, Yang AS, Fang JM, Wong CH. Analogs of zanamivir with modified C4-substituents as the inhibitors against the group-1 neuraminidases of influenza viruses. Bioorg Med Chem 2010;18:4074\u20134084.","DOI":"10.1016\/j.bmc.2010.04.010"},{"key":"10.1016\/j.bmc.2022.116647_b0070","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1021\/acsmedchemlett.9b00447","article-title":"Discovery of novel neuraminidase inhibitors by structure-based virtual screening, structural optimization, and bioassay","volume":"10","author":"Yu","year":"2019","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmc.2022.116647_b0075","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ejmech.2018.01.050","article-title":"Discovery of C-1 modified oseltamivir derivatives as potent influenza neuraminidase inhibitors","volume":"146","author":"Ju","year":"2018","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2022.116647_b0080","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1021\/jm3009713","article-title":"Structure-based design and synthesis of C-1- and C-4-modified analogs of zanamivir as neuraminidase inhibitors","volume":"56","author":"Feng","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2022.116647_b0085","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1021\/acs.orglett.5b00457","article-title":"Radical-based route to 2-(trifluoromethyl)-1,3,4-oxadiazoles and trifluoromethyl-substituted polycyclic 1,2,4-triazoles and dihydrofurans","volume":"17","author":"Qin","year":"2015","journal-title":"Org Lett"},{"key":"10.1016\/j.bmc.2022.116647_b0090","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1246\/bcsj.44.1923","article-title":"Studies of the synthesis of furan compounds. XXIV. The synthesis of 5-[2-(5-Nitro-2-furyl)-1-(4-nitrophenyl)vinyl]-1,3,4-oxadiazole and Its Related compounds","volume":"44","author":"Hirao","year":"1971","journal-title":"Bull Chem Soc Jpn"},{"key":"10.1016\/j.bmc.2022.116647_b0095","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1016\/S0040-4020(01)85962-7","article-title":"The synthesis of antihypertensive 3-(1,3,4-oxadiazol-2-yl)phenoxypropanolahines","volume":"44","author":"Schlecker","year":"1988","journal-title":"Tetrahedron"},{"key":"10.1016\/j.bmc.2022.116647_b0100","doi-asserted-by":"crossref","first-page":"9345","DOI":"10.1021\/bi800791q","article-title":"Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants","volume":"47","author":"Marinello","year":"2008","journal-title":"Biochemistry"},{"key":"10.1016\/j.bmc.2022.116647_b0105","first-page":"55","article-title":"Synthesis, antibacterial, antifungal and genotoxic activity of BIS-1,3,4-oxadiazole derivatives","volume":"54","author":"Maslat","year":"2002","journal-title":"Pol J Pharmacol"},{"key":"10.1016\/j.bmc.2022.116647_b0110","doi-asserted-by":"crossref","first-page":"1900095","DOI":"10.1002\/ardp.201900095","article-title":"A novel five-step synthetic route to 1,3,4-oxadiazole derivatives with potent \u03b1-glucosidase inhibitory potential and their in silico studies","volume":"352","author":"Iftikhar","year":"2019","journal-title":"Arch Pharm Chem Life Sci"},{"key":"10.1016\/j.bmc.2022.116647_b0115","doi-asserted-by":"crossref","first-page":"113762","DOI":"10.1016\/j.ejmech.2021.113762","article-title":"Discovery of novel thiophene derivatives as potent neuraminidase inhibitors","volume":"225","author":"Zhong","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2022.116647_b0120","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1023\/A:1020155510718","article-title":"A review of protein-small molecule docking methods","volume":"16","author":"Taylor","year":"2002","journal-title":"J Comput Aid Mol Des"},{"key":"10.1016\/j.bmc.2022.116647_b0125","unstructured":"Case DA, Darden T, Cheatham TE, III Simmerling C, Wang JM, Duke RE, et al. AMBER 12; University of California, San Francisco, 2013; 1: p 3."},{"key":"10.1016\/j.bmc.2022.116647_b0130","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1021\/ar000033j","article-title":"III Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models","volume":"33","author":"Kollman","year":"2000","journal-title":"Acc Chem Res"},{"key":"10.1016\/j.bmc.2022.116647_b0135","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/minf.201100135","article-title":"Free energy calculations by the molecular mechanics Poisson-Boltzmann surface area method","volume":"31","author":"Homeyer","year":"2012","journal-title":"Mol Inf"},{"key":"10.1016\/j.bmc.2022.116647_b0140","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1021\/ci100275a","article-title":"Assessing the performance of the MM\/PBSA and MM\/GBSA methods. 1. The accuracy of binding free energy calculations based on molecular dynamics simulations","volume":"51","author":"Hou","year":"2011","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.bmc.2022.116647_b0145","doi-asserted-by":"crossref","unstructured":"Abbasi MA, Ramzan MS, Aziz-ur-Rehman, Siddiqui SZ, Shah SAA, Hassan M, Seo S-Y, Ashraf M, Mirza B, Ismail H. N -(5-methyl-1,3-thiazol-2-yl)-2-{[5-((un) Substituted-phenyl)1,3,4-oxadiazol-2-yl]sulfanylacetamides. Unique biheterocycles as promising therapeutic agents. Russ J Bioorg Chem 2018; 44:801\u2013811.","DOI":"10.1134\/S106816201806002X"},{"key":"10.1016\/j.bmc.2022.116647_b0150","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1021\/acs.jmedchem.7b01622","article-title":"Fragment-based approach to targeting inosine-5'-monophosphate dehydrogenase (IMPDH) from Mycobacterium tuberculosis","volume":"61","author":"Trapero","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2022.116647_b0155","doi-asserted-by":"crossref","first-page":"171053","DOI":"10.1098\/rsos.171053","article-title":"Semisynthesis and insecticidal activity of some novel fraxinellone-based thioethers containing 1,3,4-oxadiazole moiety","volume":"4","author":"Guo","year":"2017","journal-title":"Roy Soc Open Sci"},{"key":"10.1016\/j.bmc.2022.116647_b0160","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1007\/s00894-012-1393-4","article-title":"A novel halogen bond and a better-known hydrogen bond coop-eration of neonicotinoid and insect nicotinic acetylcholine receptor recognition","volume":"18","author":"Duan","year":"2012","journal-title":"J Mol Model"},{"key":"10.1016\/j.bmc.2022.116647_b0165","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1021\/bi0205449","article-title":"Influenza neuramini-dase inhibitors: structure-based design of a novel inhibitor series","volume":"42","author":"Stoll","year":"2003","journal-title":"Biochemistry"},{"key":"10.1016\/j.bmc.2022.116647_b0170","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1021\/ci049844i","article-title":"Influenza virus neuraminidase inhibitors: generation and comparison of structure-based and common feature pharmacophore hypotheses and their application in virtual screening","volume":"44","author":"Steindl","year":"2004","journal-title":"J Chem Inf Comput Sci"},{"key":"10.1016\/j.bmc.2022.116647_b0175","doi-asserted-by":"crossref","unstructured":"Vay JL, Fawley W. AMBER User's Manual; 2000.","DOI":"10.2172\/783867"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089622000396?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089622000396?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T01:15:56Z","timestamp":1760836556000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089622000396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":35,"alternative-id":["S0968089622000396"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2022.116647","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis and biological evaluation of novel 1, 3, 4-oxadiazole derivatives as potent neuraminidase inhibitors","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2022.116647","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116647"}}